Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro
Main Authors: | Sun, Caixing, Yu, Yang, Wang, Lizhen, Wu, Bin, Xia, Liang, Feng, Fang, Ling, Zhiqiang, Wang, Shihua |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752767/ |
Similar Items
-
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
by: Wong, Eric T., et al.
Published: (2016) -
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
by: Ouyang, Mao, et al.
Published: (2016) -
Isthmin inhibits glioma growth through antiangiogenesis in vivo
by: Yuan, Bangqing, et al.
Published: (2012) -
Comparative Pharmacokinetics of Ginsenoside Rg3 and Ginsenoside Rh2 after Oral Administration of Ginsenoside Rg3 in Normal and Walker 256 Tumor-bearing Rats
by: Fan, He, et al.
Published: (2016) -
Genomic expression profiling and bioinformatics analysis on diabetic nephrology with ginsenoside Rg3
by: Wang, Juan, et al.
Published: (2016)